Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1927 1
1991 1
1992 2
1993 1
1996 1
2001 2
2004 1
2005 1
2006 1
2007 1
2008 2
2009 2
2010 4
2011 6
2012 3
2013 3
2014 3
2015 6
2016 4
2017 4
2018 3
2019 3
2020 4
2021 2
2022 5
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, Biemond BJ, Breems DA, Maertens J, van Marwijk Kooy M, Pabst T, de Weerdt O, Ossenkoppele GJ, van de Loosdrecht AA, Huls GA, Cornelissen JJ, Beverloo HB, Löwenberg B, Jongen-Lavrencic M, Valk PJM. Grob T, et al. Among authors: de weerdt o. Blood. 2022 Apr 14;139(15):2347-2354. doi: 10.1182/blood.2021014472. Blood. 2022. PMID: 35108372 Free PMC article.
Cytomegalovirus retinitis.
Rothova A, de Weerdt O. Rothova A, et al. Among authors: de weerdt o. Ophthalmology. 2009 Apr;116(4):817-8; author reply 818-9. doi: 10.1016/j.ophtha.2008.12.010. Ophthalmology. 2009. PMID: 19344836 No abstract available.
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
van de Loosdrecht AA, Cremers EMP, Alhan C, Duetz C, In 't Hout FEM, Visser-Wisselaar HA, Chitu DA, Verbrugge A, Cunha SM, Ossenkoppele GJ, Janssen JJWM, Klein SK, Vellenga E, Huls GA, Muus P, Langemeijer SMC, de Greef GE, Te Boekhorst PAW, Raaijmakers MHG, van Marwijk Kooy M, Legdeur MC, Wegman JJ, Deenik W, de Weerdt O, van Maanen-Lamme TM, Jobse P, van Kampen RJW, Beeker A, Wijermans PW, Biemond BJ, Tanis BC, van Esser JWJ, Schaar CG, Noordzij-Nooteboom HS, Jacobs EMG, de Graaf AO, Jongen-Lavrencic M, Stevens-Kroef MJPL, Westers TM, Jansen JH. van de Loosdrecht AA, et al. Among authors: de weerdt o. Leukemia. 2024 Apr;38(4):840-850. doi: 10.1038/s41375-024-02161-6. Epub 2024 Jan 31. Leukemia. 2024. PMID: 38297135 Free PMC article. Clinical Trial.
A functional spleen contributes to afucosylated IgG in humans.
Wojcik I, Schmidt DE, de Neef LA, Rab MAE, Meek B, de Weerdt O, Wuhrer M, van der Schoot CE, Zwaginga JJ, de Haas M, Falck D, Vidarsson G. Wojcik I, et al. Among authors: de weerdt o. Sci Rep. 2021 Dec 15;11(1):24045. doi: 10.1038/s41598-021-03196-w. Sci Rep. 2021. PMID: 34911982 Free PMC article.
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Rijneveld AW, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE, Bellido M, van Gelder M, van der Velden WJFM, Selleslag D, van Lammeren-Venema D, Halkes CJM, Fijnheer R, Havelange V, van Sluis GL, Legdeur MC, Deeren D, Gadisseur A, Sinnige HAM, Breems DA, Jaspers A, Legrand O, Terpstra WE, Boersma RS, Mazure D, Triffet A, Tick LW, Beel K, Maertens JA, Beverloo HB, Bakkus M, Homburg CHE, de Haas V, van der Velden VHJ, Cornelissen JJ; Dutch-Belgian HOVON Cooperative group. Rijneveld AW, et al. Among authors: de weerdt o. Blood Adv. 2022 Feb 22;6(4):1115-1125. doi: 10.1182/bloodadvances.2021005624. Blood Adv. 2022. PMID: 34883506 Free PMC article. Clinical Trial.
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen JJWM, Löwenberg B, Manz M, Biemond BJ, Westerweel PE, Klein SK, Fehr M, Sinnige HAM, Efthymiou A, Legdeur MCJC, Pabst T, Gregor M, van der Poel MWM, Deeren D, Tick LW, Jongen-Lavrencic M, van Obbergh F, Boersma RS, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele GJ. Janssen JJWM, et al. Among authors: de weerdt o. Leukemia. 2022 Sep;36(9):2189-2195. doi: 10.1038/s41375-022-01657-3. Epub 2022 Jul 22. Leukemia. 2022. PMID: 35869267 Clinical Trial.
Real-world costs of chronic lymphocytic leukaemia in the Netherlands.
Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, de Weerdt O, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Groot CA. Holtzer-Goor KM, et al. Among authors: de weerdt o. Leuk Res. 2014 Jan;38(1):84-90. doi: 10.1016/j.leukres.2013.10.029. Epub 2013 Nov 8. Leuk Res. 2014. PMID: 24268350
60 results